The U.S. Department of Defense has awarded Cedars-Sinai Medical Center $876,000 to support innovative biomarker research targeting non-small cell lung cancer, specifically addressing treatment resistance in patients with EGFR-driven tumors. The grant will support research in Dr. Neil Bhowmick's laboratory, focusing on Kairos Pharma's Phase 1 clinical trial of ENV105, a potential breakthrough in cancer treatment.
The research aims to identify biomarkers that could help predict and potentially overcome resistance to osimertinib, a standard treatment for EGFR-driven lung cancer. As drug resistance remains a significant challenge in cancer treatment, this study represents a critical step toward developing more personalized and effective therapeutic approaches.
ENV105, Kairos Pharma's experimental antibody, targets CD105, a protein implicated in cancer treatment resistance. By understanding how CD105 contributes to treatment failure, researchers hope to develop strategies that could restore the effectiveness of standard cancer therapies and improve patient outcomes.
This collaborative effort between Kairos Pharma and Cedars-Sinai Medical Center highlights the importance of precision medicine in oncology. The research could potentially lead to more targeted interventions for lung cancer patients who currently have limited options when standard treatments become ineffective.
The Department of Defense grant underscores the national significance of this research, recognizing the potential impact on lung cancer treatment strategies. By supporting innovative approaches to understanding and combating treatment resistance, the funding may contribute to long-term improvements in patient survival and quality of life.
